Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.
Identifieur interne : 003B20 ( PubMed/Corpus ); précédent : 003B19; suivant : 003B21Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.
Auteurs : Tracy T. Batchelor ; Paul Mulholland ; Bart Neyns ; L Burt Nabors ; Mario Campone ; Antje Wick ; Warren Mason ; Tom Mikkelsen ; Surasak Phuphanich ; Lynn S. Ashby ; John Degroot ; Rao Gattamaneni ; Lawrence Cher ; Mark Rosenthal ; Franz Payer ; Juliane M. Jürgensmeier ; Rakesh K. Jain ; A Gregory Sorensen ; John Xu ; Qi Liu ; Martin Van Den BentSource :
- Journal of clinical oncology : official journal of the American Society of Clinical Oncology [ 1527-7755 ] ; 2013.
English descriptors
- KwdEn :
- Antineoplastic Combined Chemotherapy Protocols (therapeutic use), Brain Neoplasms (drug therapy), Brain Neoplasms (mortality), Female, Follow-Up Studies, Glioblastoma (drug therapy), Glioblastoma (mortality), Humans, International Agencies, Lomustine (administration & dosage), Male, Middle Aged, Neoplasm Recurrence, Local (drug therapy), Neoplasm Recurrence, Local (mortality), Prognosis, Quinazolines (administration & dosage), Survival Rate.
- MESH :
- chemical , administration & dosage : Lomustine, Quinazolines.
- drug therapy : Brain Neoplasms, Glioblastoma, Neoplasm Recurrence, Local.
- mortality : Brain Neoplasms, Glioblastoma, Neoplasm Recurrence, Local.
- therapeutic use : Antineoplastic Combined Chemotherapy Protocols.
- Female, Follow-Up Studies, Humans, International Agencies, Male, Middle Aged, Prognosis, Survival Rate.
Abstract
A randomized, phase III, placebo-controlled, partially blinded clinical trial (REGAL [Recent in in Glioblastoma Alone and With Lomustine]) was conducted to determine the efficacy of cediranib, an oral pan-vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, either as monotherapy or in combination with lomustine versus lomustine in patients with recurrent glioblastoma.
DOI: 10.1200/JCO.2012.47.2464
PubMed: 23940216
Links to Exploration step
pubmed:23940216Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.</title><author><name sortKey="Batchelor, Tracy T" sort="Batchelor, Tracy T" uniqKey="Batchelor T" first="Tracy T" last="Batchelor">Tracy T. Batchelor</name><affiliation><nlm:affiliation>Tracy T. Batchelor, Rakesh K. Jain, and Gregory Sorensen, Massachusetts General Hospital, Boston, MA; Paul Mulholland, University College London, London; Rao Gattamaneni, the Christie Foundation Trust Hospital, Manchester, United Kingdom; Bart Neyns, Universitair Ziekenhuis Brussel, Brussels, Belgium; L. Burt Nabors, University of Alabama at Birmingham, Birmingham, AL; Mario Campone, Centre Rene Gauducheau, Saint-Herblain, France; Antje Wick, University of Heidelberg, Heidelberg, Germany; Warren Mason, Princess Margaret Hospital, Toronto, Ontario, Canada; Tom Mikkelsen, Henry Ford Hospital, Detroit, MI; Surasak Phuphanich, Cedars-Sinai Medical Center, Los Angeles, CA; Lynn S. Ashby, Barrow Neurological Institute, Phoenix, AZ; John DeGroot, MD Anderson Cancer Center, Houston, TX; Lawrence Cher, Austin Health Cancer Services; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Australia; Franz Payer, Medical University, Graz, Austria; Juliane M. Jürgensmeier, John Xu, and Qi Liu, AstraZeneca, Wilmington, DE; and Martin van den Bent, Erasmus University Medical Center-Daniel den Hoed Cancer Center, Rotterdam, the Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Mulholland, Paul" sort="Mulholland, Paul" uniqKey="Mulholland P" first="Paul" last="Mulholland">Paul Mulholland</name></author><author><name sortKey="Neyns, Bart" sort="Neyns, Bart" uniqKey="Neyns B" first="Bart" last="Neyns">Bart Neyns</name></author><author><name sortKey="Nabors, L Burt" sort="Nabors, L Burt" uniqKey="Nabors L" first="L Burt" last="Nabors">L Burt Nabors</name></author><author><name sortKey="Campone, Mario" sort="Campone, Mario" uniqKey="Campone M" first="Mario" last="Campone">Mario Campone</name></author><author><name sortKey="Wick, Antje" sort="Wick, Antje" uniqKey="Wick A" first="Antje" last="Wick">Antje Wick</name></author><author><name sortKey="Mason, Warren" sort="Mason, Warren" uniqKey="Mason W" first="Warren" last="Mason">Warren Mason</name></author><author><name sortKey="Mikkelsen, Tom" sort="Mikkelsen, Tom" uniqKey="Mikkelsen T" first="Tom" last="Mikkelsen">Tom Mikkelsen</name></author><author><name sortKey="Phuphanich, Surasak" sort="Phuphanich, Surasak" uniqKey="Phuphanich S" first="Surasak" last="Phuphanich">Surasak Phuphanich</name></author><author><name sortKey="Ashby, Lynn S" sort="Ashby, Lynn S" uniqKey="Ashby L" first="Lynn S" last="Ashby">Lynn S. Ashby</name></author><author><name sortKey="Degroot, John" sort="Degroot, John" uniqKey="Degroot J" first="John" last="Degroot">John Degroot</name></author><author><name sortKey="Gattamaneni, Rao" sort="Gattamaneni, Rao" uniqKey="Gattamaneni R" first="Rao" last="Gattamaneni">Rao Gattamaneni</name></author><author><name sortKey="Cher, Lawrence" sort="Cher, Lawrence" uniqKey="Cher L" first="Lawrence" last="Cher">Lawrence Cher</name></author><author><name sortKey="Rosenthal, Mark" sort="Rosenthal, Mark" uniqKey="Rosenthal M" first="Mark" last="Rosenthal">Mark Rosenthal</name></author><author><name sortKey="Payer, Franz" sort="Payer, Franz" uniqKey="Payer F" first="Franz" last="Payer">Franz Payer</name></author><author><name sortKey="Jurgensmeier, Juliane M" sort="Jurgensmeier, Juliane M" uniqKey="Jurgensmeier J" first="Juliane M" last="Jürgensmeier">Juliane M. Jürgensmeier</name></author><author><name sortKey="Jain, Rakesh K" sort="Jain, Rakesh K" uniqKey="Jain R" first="Rakesh K" last="Jain">Rakesh K. Jain</name></author><author><name sortKey="Sorensen, A Gregory" sort="Sorensen, A Gregory" uniqKey="Sorensen A" first="A Gregory" last="Sorensen">A Gregory Sorensen</name></author><author><name sortKey="Xu, John" sort="Xu, John" uniqKey="Xu J" first="John" last="Xu">John Xu</name></author><author><name sortKey="Liu, Qi" sort="Liu, Qi" uniqKey="Liu Q" first="Qi" last="Liu">Qi Liu</name></author><author><name sortKey="Van Den Bent, Martin" sort="Van Den Bent, Martin" uniqKey="Van Den Bent M" first="Martin" last="Van Den Bent">Martin Van Den Bent</name></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2013">2013</date><idno type="RBID">pubmed:23940216</idno><idno type="pmid">23940216</idno><idno type="doi">10.1200/JCO.2012.47.2464</idno><idno type="wicri:Area/PubMed/Corpus">003B20</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003B20</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.</title><author><name sortKey="Batchelor, Tracy T" sort="Batchelor, Tracy T" uniqKey="Batchelor T" first="Tracy T" last="Batchelor">Tracy T. Batchelor</name><affiliation><nlm:affiliation>Tracy T. Batchelor, Rakesh K. Jain, and Gregory Sorensen, Massachusetts General Hospital, Boston, MA; Paul Mulholland, University College London, London; Rao Gattamaneni, the Christie Foundation Trust Hospital, Manchester, United Kingdom; Bart Neyns, Universitair Ziekenhuis Brussel, Brussels, Belgium; L. Burt Nabors, University of Alabama at Birmingham, Birmingham, AL; Mario Campone, Centre Rene Gauducheau, Saint-Herblain, France; Antje Wick, University of Heidelberg, Heidelberg, Germany; Warren Mason, Princess Margaret Hospital, Toronto, Ontario, Canada; Tom Mikkelsen, Henry Ford Hospital, Detroit, MI; Surasak Phuphanich, Cedars-Sinai Medical Center, Los Angeles, CA; Lynn S. Ashby, Barrow Neurological Institute, Phoenix, AZ; John DeGroot, MD Anderson Cancer Center, Houston, TX; Lawrence Cher, Austin Health Cancer Services; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Australia; Franz Payer, Medical University, Graz, Austria; Juliane M. Jürgensmeier, John Xu, and Qi Liu, AstraZeneca, Wilmington, DE; and Martin van den Bent, Erasmus University Medical Center-Daniel den Hoed Cancer Center, Rotterdam, the Netherlands.</nlm:affiliation></affiliation></author><author><name sortKey="Mulholland, Paul" sort="Mulholland, Paul" uniqKey="Mulholland P" first="Paul" last="Mulholland">Paul Mulholland</name></author><author><name sortKey="Neyns, Bart" sort="Neyns, Bart" uniqKey="Neyns B" first="Bart" last="Neyns">Bart Neyns</name></author><author><name sortKey="Nabors, L Burt" sort="Nabors, L Burt" uniqKey="Nabors L" first="L Burt" last="Nabors">L Burt Nabors</name></author><author><name sortKey="Campone, Mario" sort="Campone, Mario" uniqKey="Campone M" first="Mario" last="Campone">Mario Campone</name></author><author><name sortKey="Wick, Antje" sort="Wick, Antje" uniqKey="Wick A" first="Antje" last="Wick">Antje Wick</name></author><author><name sortKey="Mason, Warren" sort="Mason, Warren" uniqKey="Mason W" first="Warren" last="Mason">Warren Mason</name></author><author><name sortKey="Mikkelsen, Tom" sort="Mikkelsen, Tom" uniqKey="Mikkelsen T" first="Tom" last="Mikkelsen">Tom Mikkelsen</name></author><author><name sortKey="Phuphanich, Surasak" sort="Phuphanich, Surasak" uniqKey="Phuphanich S" first="Surasak" last="Phuphanich">Surasak Phuphanich</name></author><author><name sortKey="Ashby, Lynn S" sort="Ashby, Lynn S" uniqKey="Ashby L" first="Lynn S" last="Ashby">Lynn S. Ashby</name></author><author><name sortKey="Degroot, John" sort="Degroot, John" uniqKey="Degroot J" first="John" last="Degroot">John Degroot</name></author><author><name sortKey="Gattamaneni, Rao" sort="Gattamaneni, Rao" uniqKey="Gattamaneni R" first="Rao" last="Gattamaneni">Rao Gattamaneni</name></author><author><name sortKey="Cher, Lawrence" sort="Cher, Lawrence" uniqKey="Cher L" first="Lawrence" last="Cher">Lawrence Cher</name></author><author><name sortKey="Rosenthal, Mark" sort="Rosenthal, Mark" uniqKey="Rosenthal M" first="Mark" last="Rosenthal">Mark Rosenthal</name></author><author><name sortKey="Payer, Franz" sort="Payer, Franz" uniqKey="Payer F" first="Franz" last="Payer">Franz Payer</name></author><author><name sortKey="Jurgensmeier, Juliane M" sort="Jurgensmeier, Juliane M" uniqKey="Jurgensmeier J" first="Juliane M" last="Jürgensmeier">Juliane M. Jürgensmeier</name></author><author><name sortKey="Jain, Rakesh K" sort="Jain, Rakesh K" uniqKey="Jain R" first="Rakesh K" last="Jain">Rakesh K. Jain</name></author><author><name sortKey="Sorensen, A Gregory" sort="Sorensen, A Gregory" uniqKey="Sorensen A" first="A Gregory" last="Sorensen">A Gregory Sorensen</name></author><author><name sortKey="Xu, John" sort="Xu, John" uniqKey="Xu J" first="John" last="Xu">John Xu</name></author><author><name sortKey="Liu, Qi" sort="Liu, Qi" uniqKey="Liu Q" first="Qi" last="Liu">Qi Liu</name></author><author><name sortKey="Van Den Bent, Martin" sort="Van Den Bent, Martin" uniqKey="Van Den Bent M" first="Martin" last="Van Den Bent">Martin Van Den Bent</name></author></analytic><series><title level="j">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</title><idno type="eISSN">1527-7755</idno><imprint><date when="2013" type="published">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols (therapeutic use)</term><term>Brain Neoplasms (drug therapy)</term><term>Brain Neoplasms (mortality)</term><term>Female</term><term>Follow-Up Studies</term><term>Glioblastoma (drug therapy)</term><term>Glioblastoma (mortality)</term><term>Humans</term><term>International Agencies</term><term>Lomustine (administration & dosage)</term><term>Male</term><term>Middle Aged</term><term>Neoplasm Recurrence, Local (drug therapy)</term><term>Neoplasm Recurrence, Local (mortality)</term><term>Prognosis</term><term>Quinazolines (administration & dosage)</term><term>Survival Rate</term></keywords><keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en"><term>Lomustine</term><term>Quinazolines</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Brain Neoplasms</term><term>Glioblastoma</term><term>Neoplasm Recurrence, Local</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>Brain Neoplasms</term><term>Glioblastoma</term><term>Neoplasm Recurrence, Local</term></keywords><keywords scheme="MESH" qualifier="therapeutic use" xml:lang="en"><term>Antineoplastic Combined Chemotherapy Protocols</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Female</term><term>Follow-Up Studies</term><term>Humans</term><term>International Agencies</term><term>Male</term><term>Middle Aged</term><term>Prognosis</term><term>Survival Rate</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">A randomized, phase III, placebo-controlled, partially blinded clinical trial (REGAL [Recent in in Glioblastoma Alone and With Lomustine]) was conducted to determine the efficacy of cediranib, an oral pan-vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, either as monotherapy or in combination with lomustine versus lomustine in patients with recurrent glioblastoma.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">23940216</PMID><DateCreated><Year>2013</Year><Month>09</Month><Day>09</Day></DateCreated><DateCompleted><Year>2013</Year><Month>11</Month><Day>22</Day></DateCompleted><DateRevised><Year>2016</Year><Month>12</Month><Day>15</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1527-7755</ISSN><JournalIssue CitedMedium="Internet"><Volume>31</Volume><Issue>26</Issue><PubDate><Year>2013</Year><Month>Sep</Month><Day>10</Day></PubDate></JournalIssue><Title>Journal of clinical oncology : official journal of the American Society of Clinical Oncology</Title><ISOAbbreviation>J. Clin. Oncol.</ISOAbbreviation></Journal><ArticleTitle>Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.</ArticleTitle><Pagination><MedlinePgn>3212-8</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1200/JCO.2012.47.2464</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">A randomized, phase III, placebo-controlled, partially blinded clinical trial (REGAL [Recent in in Glioblastoma Alone and With Lomustine]) was conducted to determine the efficacy of cediranib, an oral pan-vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor, either as monotherapy or in combination with lomustine versus lomustine in patients with recurrent glioblastoma.</AbstractText><AbstractText Label="PATIENTS AND METHODS" NlmCategory="METHODS">Patients (N = 325) with recurrent glioblastoma who previously received radiation and temozolomide were randomly assigned 2:2:1 to receive (1) cediranib (30 mg) monotherapy; (2) cediranib (20 mg) plus lomustine (110 mg/m(2)); (3) lomustine (110 mg/m(2)) plus a placebo. The primary end point was progression-free survival based on blinded, independent radiographic assessment of postcontrast T1-weighted and noncontrast T2-weighted magnetic resonance imaging (MRI) brain scans.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The primary end point of progression-free survival (PFS) was not significantly different for either cediranib alone (hazard ratio [HR] = 1.05; 95% CI, 0.74 to 1.50; two-sided P = .90) or cediranib in combination with lomustine (HR = 0.76; 95% CI, 0.53 to 1.08; two-sided P = .16) versus lomustine based on independent or local review of postcontrast T1-weighted MRI.</AbstractText><AbstractText Label="CONCLUSION" NlmCategory="CONCLUSIONS">This study did not meet its primary end point of PFS prolongation with cediranib either as monotherapy or in combination with lomustine versus lomustine in patients with recurrent glioblastoma, although cediranib showed evidence of clinical activity on some secondary end points including time to deterioration in neurologic status and corticosteroid-sparing effects.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Batchelor</LastName><ForeName>Tracy T</ForeName><Initials>TT</Initials><AffiliationInfo><Affiliation>Tracy T. Batchelor, Rakesh K. Jain, and Gregory Sorensen, Massachusetts General Hospital, Boston, MA; Paul Mulholland, University College London, London; Rao Gattamaneni, the Christie Foundation Trust Hospital, Manchester, United Kingdom; Bart Neyns, Universitair Ziekenhuis Brussel, Brussels, Belgium; L. Burt Nabors, University of Alabama at Birmingham, Birmingham, AL; Mario Campone, Centre Rene Gauducheau, Saint-Herblain, France; Antje Wick, University of Heidelberg, Heidelberg, Germany; Warren Mason, Princess Margaret Hospital, Toronto, Ontario, Canada; Tom Mikkelsen, Henry Ford Hospital, Detroit, MI; Surasak Phuphanich, Cedars-Sinai Medical Center, Los Angeles, CA; Lynn S. Ashby, Barrow Neurological Institute, Phoenix, AZ; John DeGroot, MD Anderson Cancer Center, Houston, TX; Lawrence Cher, Austin Health Cancer Services; Mark Rosenthal, Royal Melbourne Hospital, Melbourne, Australia; Franz Payer, Medical University, Graz, Austria; Juliane M. Jürgensmeier, John Xu, and Qi Liu, AstraZeneca, Wilmington, DE; and Martin van den Bent, Erasmus University Medical Center-Daniel den Hoed Cancer Center, Rotterdam, the Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mulholland</LastName><ForeName>Paul</ForeName><Initials>P</Initials></Author><Author ValidYN="Y"><LastName>Neyns</LastName><ForeName>Bart</ForeName><Initials>B</Initials></Author><Author ValidYN="Y"><LastName>Nabors</LastName><ForeName>L Burt</ForeName><Initials>LB</Initials></Author><Author ValidYN="Y"><LastName>Campone</LastName><ForeName>Mario</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Wick</LastName><ForeName>Antje</ForeName><Initials>A</Initials></Author><Author ValidYN="Y"><LastName>Mason</LastName><ForeName>Warren</ForeName><Initials>W</Initials></Author><Author ValidYN="Y"><LastName>Mikkelsen</LastName><ForeName>Tom</ForeName><Initials>T</Initials></Author><Author ValidYN="Y"><LastName>Phuphanich</LastName><ForeName>Surasak</ForeName><Initials>S</Initials></Author><Author ValidYN="Y"><LastName>Ashby</LastName><ForeName>Lynn S</ForeName><Initials>LS</Initials></Author><Author ValidYN="Y"><LastName>Degroot</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Gattamaneni</LastName><ForeName>Rao</ForeName><Initials>R</Initials></Author><Author ValidYN="Y"><LastName>Cher</LastName><ForeName>Lawrence</ForeName><Initials>L</Initials></Author><Author ValidYN="Y"><LastName>Rosenthal</LastName><ForeName>Mark</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Payer</LastName><ForeName>Franz</ForeName><Initials>F</Initials></Author><Author ValidYN="Y"><LastName>Jürgensmeier</LastName><ForeName>Juliane M</ForeName><Initials>JM</Initials></Author><Author ValidYN="Y"><LastName>Jain</LastName><ForeName>Rakesh K</ForeName><Initials>RK</Initials></Author><Author ValidYN="Y"><LastName>Sorensen</LastName><ForeName>A Gregory</ForeName><Initials>AG</Initials></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>John</ForeName><Initials>J</Initials></Author><Author ValidYN="Y"><LastName>Liu</LastName><ForeName>Qi</ForeName><Initials>Q</Initials></Author><Author ValidYN="Y"><LastName>van den Bent</LastName><ForeName>Martin</ForeName><Initials>M</Initials></Author></AuthorList><Language>eng</Language><DataBankList CompleteYN="Y"><DataBank><DataBankName>ClinicalTrials.gov</DataBankName><AccessionNumberList><AccessionNumber>NCT00777153</AccessionNumber></AccessionNumberList></DataBank></DataBankList><GrantList CompleteYN="Y"><Grant><GrantID>K24 CA125440</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D017428">Clinical Trial, Phase III</PublicationType><PublicationType UI="D003160">Comparative Study</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2013</Year><Month>08</Month><Day>12</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>J Clin Oncol</MedlineTA><NlmUniqueID>8309333</NlmUniqueID><ISSNLinking>0732-183X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D011799">Quinazolines</NameOfSubstance></Chemical><Chemical><RegistryNumber>7BRF0Z81KG</RegistryNumber><NameOfSubstance UI="D008130">Lomustine</NameOfSubstance></Chemical><Chemical><RegistryNumber>NQU9IPY4K9</RegistryNumber><NameOfSubstance UI="C500926">cediranib</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="Cites"><RefSource>Trans Am Neurol Assoc. 1976;101:217-20</RefSource><PMID Version="1">1028239</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Cell. 2007 Jan;11(1):83-95</RefSource><PMID Version="1">17222792</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2009 Feb 10;27(5):740-5</RefSource><PMID Version="1">19114704</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Lancet Oncol. 2009 May;10(5):459-66</RefSource><PMID Version="1">19269895</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2009 Oct 1;27(28):4733-40</RefSource><PMID Version="1">19720927</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Oncologist. 2009 Nov;14(11):1131-8</RefSource><PMID Version="1">19897538</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2010 Jan 1;28(1):49-55</RefSource><PMID Version="1">19917841</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2010 Mar 1;28(7):1168-74</RefSource><PMID Version="1">20124186</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2010 Apr 10;28(11):1963-72</RefSource><PMID Version="1">20231676</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 2010 Jun 10;28(17):2817-23</RefSource><PMID Version="1">20458050</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 1999 Aug;17(8):2572-8</RefSource><PMID Version="1">10561324</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Treat Rep. 1976 Jun;60(6):719-24</RefSource><PMID Version="1">954010</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Rev Neurosci. 2007 Aug;8(8):610-22</RefSource><PMID Version="1">17643088</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>J Clin Oncol. 1990 Jul;8(7):1277-80</RefSource><PMID Version="1">2358840</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 1992 Oct 29;359(6398):843-5</RefSource><PMID Version="1">1279431</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nature. 1994 Feb 10;367(6463):576-9</RefSource><PMID Version="1">8107827</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 1995 Mar 1;55(5):1189-93</RefSource><PMID Version="1">7532545</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Int J Cancer. 1999 Feb 19;84(1):10-8</RefSource><PMID Version="1">9988225</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Science. 1999 Jun 18;284(5422):1994-8</RefSource><PMID Version="1">10373119</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Cell. 2004 Dec;6(6):553-63</RefSource><PMID Version="1">15607960</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>N Engl J Med. 2005 Mar 10;352(10):987-96</RefSource><PMID Version="1">15758009</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Cancer Res. 2005 May 15;65(10):4389-400</RefSource><PMID Version="1">15899831</PMID></CommentsCorrections><CommentsCorrections RefType="Cites"><RefSource>Nat Clin Pract Oncol. 2006 Jan;3(1):24-40</RefSource><PMID Version="1">16407877</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Clin Oncol. 2014 Jul 20;32(21):2273-4</RefSource><PMID Version="1">24934784</PMID></CommentsCorrections><CommentsCorrections RefType="CommentIn"><RefSource>J Clin Oncol. 2014 Jul 20;32(21):2272</RefSource><PMID Version="1">24934790</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000971" MajorTopicYN="N">Antineoplastic Combined Chemotherapy Protocols</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001932" MajorTopicYN="N">Brain Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005909" MajorTopicYN="N">Glioblastoma</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007390" MajorTopicYN="N">International Agencies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008130" MajorTopicYN="N">Lomustine</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009364" MajorTopicYN="N">Neoplasm Recurrence, Local</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011379" MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011799" MajorTopicYN="N">Quinazolines</DescriptorName><QualifierName UI="Q000008" MajorTopicYN="N">administration & dosage</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015996" MajorTopicYN="N">Survival Rate</DescriptorName></MeshHeading></MeshHeadingList><OtherID Source="NLM">PMC4021043</OtherID></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2013</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2013</Year><Month>8</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2013</Year><Month>12</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">23940216</ArticleId><ArticleId IdType="pii">JCO.2012.47.2464</ArticleId><ArticleId IdType="doi">10.1200/JCO.2012.47.2464</ArticleId><ArticleId IdType="pmc">PMC4021043</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003B20 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 003B20 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:23940216
|texte= Phase III randomized trial comparing the efficacy of cediranib as monotherapy, and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:23940216" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |